113P Clinical overstaging in pathologic stage I non-small cell lung cancer: Prognostic implications

MLA

N.O.T. Deboever, et al. “113P Clinical Overstaging in Pathologic Stage I Non-Small Cell Lung Cancer: Prognostic Implications.” Journal of Thoracic Oncology, vol. 18, Apr. 2023, pp. S104–05. EBSCOhost, https://doi.org/10.1016/s1556-0864(23)00368-4.

APA

N.O.T. Deboever, M. Eisenberg, W.L. Hofstetter, R. Mehran, R. Rajaram, D. Rice, S. Swisher, G. Walsh, A. Vaporciyan, B. Sepesi, & M. Antonoff. (2023). 113P Clinical overstaging in pathologic stage I non-small cell lung cancer: Prognostic implications. Journal of Thoracic Oncology, 18, S104–S105. https://doi.org/10.1016/s1556-0864(23)00368-4

Chicago

N.O.T. Deboever, M. Eisenberg, W.L. Hofstetter, R. Mehran, R. Rajaram, D. Rice, S. Swisher, et al. 2023. “113P Clinical Overstaging in Pathologic Stage I Non-Small Cell Lung Cancer: Prognostic Implications.” Journal of Thoracic Oncology 18 (April): S104–5. doi:10.1016/s1556-0864(23)00368-4.